HIMS Rally Hides Insider Selling After Record EPS Misses
HIMS stock hit a 2026 high after securing a $400 million JPMorgan working capital facility, yet five C-suite executives unloaded $3.61 million in shares during August following two consecutive record
HIMS Hits 2026 High as C-Suite Sold the Rally
NEW YORK, September 14 —
Hims & Hers Health, Inc. (HIMS) struck a 2026 price high this week after reports of a $400 million JPMorgan working capital facility. Yet five C-suite executives unloaded a combined $3.61 million in open-market shares in August at prices that bracket today's rally, following two consecutive record EPS misses, with zero insider purchases recorded.
- Q2 EPS -$0.37 vs. -$0.05 consensus, a -640% miss; TTM revenue $2.58B, up 38.2% year over year.
- Five executives sold $3.61M open-market shares in August; CFO sold $1.94M at $35.09 in June, before Q2.
- Short interest 28.3% of float; stock at $27.51, $6.42B market cap, 33.7x forward P/E on a net-loss company.
Five Executives Sold; None Bought
The five open-market sellers — CFO Oluyemi Okupe, CLO Soleil Boughton, CPO Deborah Autor, CTO Mohamed Elshenawy, and COO Michael Chi — disposed of shares between $27.55 and $29.99 from August 14 through September 2, a range that tracks today's stock price. Hims & Hers Health is a telehealth platform selling prescription and OTC products across sexual health, hair care, weight loss, mental health, and dermatology in nine countries; see Hims & Hers Health, Inc.'s latest numbers for current trading data. The most pointed transaction predates the summer: Okupe sold 55,383 shares at $35.09 on June 18, collecting $1.94 million at a price $7.58 above today's level, before Q2 results appeared in the August 10 8-K.
The Rally Arrives After Two Record EPS Misses
The $400 million working capital facility arrives after Hims & Hers posted its two worst EPS results on record. The quarter before Q2 2026 saw EPS of -$0.40 against a consensus of +, a -1,681.7% surprise miss that itself followed a positive $0.08 beat, swinging the trajectory sharply negative over two consecutive quarters. A securities fraud class action, filed by Kahn Swick & Foti, LLC per a PR Newswire release, links claims to deceptive privacy and billing practices and attributes more than a 14% stock decline to those disclosures. Net debt stands at $0.71 billion and 28.3% of the float remains short.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| HIMS | $6.4B | 33.7x | -49.0% |
| OSCR | $10.1B | 17.4x | +75.0% |
| NBIS | $61.0B | n/a | +146.9% |
| TEM | $10.6B | n/a | -30.7% |
| IREN | $17.3B | n/a | +18.0% |
| SOFI | $22.4B | 20.9x | -37.4% |
What Q3 Earnings Must Deliver
The thesis test arrives at Q3 2026 earnings. At 33.7x forward P/E on a company generating a TTM net loss of -$0.64 per share, the market has priced in an earnings recovery, not a third consecutive miss. The Q3 EPS figure is the first credible gauge of whether the JPMorgan facility and new platform partners translate into margin progress; 69.5% gross margins show the cost structure can support profitability once losses moderate. Analyst consensus sits at $31.29 and Basis Report rates HIMS a HOLD with a $30.00 target; See the full DCF model and price target →. Whether August's insider selling proves well-timed hinges on that single line.
Current fundamentals, valuation and filing history for Hims & Hers Health, Inc. (HIMS) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What is HIMS Hers Health's business?
Hims Hers Health is a telehealth platform selling prescription and OTC products across sexual health, hair care, weight loss, mental health, and dermatology in nine countries.
How much did HIMS insiders sell in August?
Five C-suite executives sold a combined $3.61 million in open-market shares between August 14 and September 2 at prices ranging from $27.55 to $29.99. The CFO sold $1.94 million at $35.09 in June, before Q2 results were announced.
What were HIMS's recent earnings results?
HIMS posted two consecutive record EPS misses. Q2 2026 EPS was -$0.37 versus consensus of -$0.05, a -640% miss. The prior quarter saw -$0.40 versus consensus of +$0.026, a -1,681.7% miss.
What is HIMS's current valuation?
At $27.51 per share, HIMS trades at 33.7x forward P/E on a net-loss company with a TTM net loss of -$0.64 per share and $6.42 billion market cap. Short interest represents 28.3% of float.
What did Basis Report say about HIMS?
Basis Report rates HIMS a HOLD with a $30.00 price target. Analyst consensus sits at $31.29. The Q3 2026 earnings report is the first real gauge of whether the working capital facility translates into margin progress.
Hims & Hers Health stock reportedly reached a 2026 price high this week on news of a $400 million JPMorgan working capital facility and eight new platform partners — yet five C-suite executives were net sellers of open-market shares at exactly these price levels in the weeks following the company's second consecutive massive earnings miss.